Chunk #29 — 3. Pharmacogenetic Studies of Treatment for Alcohol Use Disorder in Individuals of Diverse Ancestries — 3.4 Individuals of American Indian/Alaska Native Ancestry
trial, relative to placebo. Combination treatment with sertraline did not have a significantly different effect on alcohol use outcomes relative to NTX alone in the total sample or the subsample of AI/AN individuals. A pharmacogenetic analysis was also conducted in this study to investigate whether the presence of the Asp40 allele moderated the results. Alcohol-related treatment outcomes, such as drinking-related consequences, which were significantly reduced with NTX, did not depend on the presence of the G allele (17 of the 92 genotyped participants), as the results were nearly identical for the 75 A/A homozygotes compared to the total sample (92 genotyped participants). These findings suggest that in individuals of AI/AN ancestry, it is possible that while NTX treatment alone is effective at reducing drinking-related consequences and increasing the number of days abstinent, The frequency of the G allele in American Indians (13%)58 is similar to the frequency in individuals of European ancestry (15%)44, but much less frequent than in individuals of Asian ancestry (~40–50%)19, 44. Thus, OPRM1 genotype may not be influencing the efficacy of NTX in individuals of AI/AN ancestry. While these findings need to be confirmed with additional clinical trials that include individuals of AI/AN ancestry, and larger
